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Abstract: 
BACKGROUND: Alkaptonuria (AKU) is present from birth, yet clinical effects 
are considered to appear later in life. Morbidity of AKU, considered 
irrervesible, is secondary to ochronosis. Age of ochronosis onset is not 
clearly known. Nitisinone profoundly lowers homogentisic acid (HGA), the 
metabolic defect in AKU. Nitisinone also arrests ochronosis and slows 
progression of AKU. However, tyrosinaemia post-nitisinone has been 
associated with corneal keratopathy, rash and cognitive impairment in HT 
1. The optimal time to start nitisinone in AKU is unknown.  
 
METHODS: In an open, cross-sectional, single site study, 32 AKU patients 
were to be recruited. The primary outcome was presence of ochronosis in 
an ear biopsy. Secondary outcomes included analysis of photographs of 
eyes/ears, serum/urine HGA, markers of tissue 
damage/inflammation/oxidation, MRI imaging, gait, quality of life and 
Alkaptonuria Severity Score Index (qAKUSSI).  
 
RESULTS: Thirty patients, with mean age (SD) 38 (14) years were 
recruited. Percentage pigmentation within ear biopsies increased with age. 
Ear pigmentation was detected in a 20 year old female implying ochronosis 
can start in patients before the age of 20. Gait and qAKUSSI were outside 
the normal range in all the AKU patients.  
 
CONCLUSIONS: Ochronosis can be present before age 20 years.  
 
What does this study add: It shows for the first time that features of AKU 
and subclinical ochronosis can be present from age 16 years.  
 
Impact on clinical practice: This study supports nitisinone therapy from age 
16 years in AKU. An AKU paediatric study is needed in those younger than 
16 years.  
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Abstract 
 
BACKGROUND: Alkaptonuria (AKU) is present from birth, yet clinical effects are considered to 
appear later in life. Morbidity of AKU, considered irrervesible, is secondary to ochronosis. Age of 
ochronosis onset is not clearly known. Nitisinone profoundly lowers homogentisic acid (HGA), the 
metabolic defect in AKU. Nitisinone also arrests ochronosis and slows progression of AKU. However, 
tyrosinaemia post-nitisinone has been associated with corneal keratopathy, rash and cognitive 
impairment in HT 1. The optimal time to start nitisinone in AKU is unknown. 
 
METHODS: In an open, cross-sectional, single site study, 32 AKU patients were to be recruited. The 
primary outcome was presence of ochronosis in an ear biopsy. Secondary outcomes included analysis 
of photographs of eyes/ears, serum/urine HGA, markers of tissue damage/inflammation/oxidation, 
MRI imaging, gait, quality of life and Alkaptonuria Severity Score Index (qAKUSSI). 
 
RESULTS: Thirty patients, with mean age (SD) 38 (14) years were recruited. Percentage 
pigmentation within ear biopsies increased with age. Ear pigmentation was detected in a 20 year old 
female implying ochronosis can start in patients before the age of 20. Gait and qAKUSSI were outside 
the normal range in all the AKU patients. 
 
CONCLUSIONS: Ochronosis can be present before age 20 years. 
 
What does this study add: It shows for the first time that features of AKU and subclinical ochronosis 
can be present from age 16 years. 
 
Impact on clinical practice: This study supports nitisinone therapy from age 16 years in AKU. An 
AKU paediatric study is needed in those younger than 16 years.  
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Key messages 
 
• Nitisinone arrests ochronosis and decreases progression of alkaptonuria 
 
• Nitisinone increases circulating tyrosine and consequences such as corneal keratopathy, 
rashes and cognitive impairment 
 
• Presence of irreversible ochronosis can justify nitisinone therapy in younger patients 
 
• AKU features established in patients as young as 16 – 20 years, suggesting that nitisinone 
therapy can be justified from age 16 years 
 
• Further studies needed to determine whether nitisinone should be administered to AKU 
patients younger than 16 years  
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Background 
Alkaptonuria (AKU) (OMIM#203500) is a rare genetic deficiency of homogentisate dioxygenase 
(HGD) (EC:1.13.11.5), characterised by high circulating homogentisic acid (HGA).[1] The frequency 
of AKU is around 1 in 250,000 to 1 in a 1,000,000 in most populations worldwide. Deposition of 
HGA in connective tissue as pigment in AKU is termed ochronosis.[2] Debilitating manifestations of 
AKU are due to ochronosis including premature arthritis, cardiac valve disease, fractures, muscle and 
tendon ruptures.[3] Despite the presence of the defect from birth, apart from dark urine, and 
sometimes renal stones, there are few osteoarticular symptoms until around age 25 years.[4]   
 
A recent study has shown that nitisinone, an inhibitor of p-hydroxyphenylpyruvate dioxygenase 
(EC:1.13.11.27) is effective in AKU.[5, 6, 7, 8] Nitisinone decreases circulating HGA, inhibits 
ochronosis in AKU mice and humans, slowing progression of human AKU, but is expensive.[9, 10] It 
is an imperfect treatment producing a different metabolic block, characterised by tyrosinaemia; toxic 
consequences, such as corneal keratopathy, eczema like skin rash and cognitive impairment can 
ensue.[11]  
 
AKU is not fully reversible and would benefit from early treatment. Mouse studies show that 
nitisinone can prevent onset of ochronosis when started soon after birth, and arrest ochronosis when 
started later.[9, 10] Mouse studies revealed ochronotic pigment laid down in knee joints as early as 15 
weeks.[9]  These findings highlight the concern that subclinical ochronosis could be damaging 
connective tissues early in life.  Starting nitisinone later in AKU is expected to result in residual 
disease as AKU is irreversible.[4] Identifying when ochronosis takes hold in AKU is important, as this 
information would allow optimal use of nitisinone, in terms of when to begin treatment. 
 
The SOFIA (Subclinical Ochronosis Features In Alkaptonuria) study was designed to identify the 
earliest age when ochronosis, microscopic and macroscopic, can be detected in patients and at what 
age it might be appropriate to begin nitisinone treatment.   
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Methods 
PATIENTS 
AKU patients, verified by elevated HGA levels, and at least 16 years old were eligible for 
inclusion. A non-AKU control group was also selected. The United Kingdom NRES granted 
ethics approval (REC NO:15/NW/0749; IRAS:180968). 
 
STUDY DESIGN  
SOFIA was an open, cross-sectional, single-site (Royal Liverpool University Hospital) study, 32 AKU 
patients were to be recruited (2 males, 2 females in each age interval: 16-20, 21-25, 26-30, 31-35, 36-
40, 41-45, 46-50, over-50) covering the age spread of non-ochronotic and ochronotic groups. The 
primary outcome was the amount of ochronosis measured in ear biopsies. The secondary outcomes 
were: visible ochronosis quantification in eyes and ears; MRI examination; deviation in gait; modified 
qAKUSSI (questionnaire Alkaptonuria Severity Score Index); circulating and urine HGA; 
inflammation, cartilage damage, bone and other tissue biomarkers, and quality of life.  
 
ASSESSMENTS 
Ear cartilage: a 4mm diameter, 1-2mm thick biopsy was taken from the conchal bowl of the ear and 
stored using a standardised protocol. Ochronosis was measured by % light absorbance in microscope 
photographs (non-ochronotic tissue=0, completely ochronotic tissue=100)  (see Supplementary 
Material). 
Standardised photographs of eyes and ears were scored for ochronosis: for eyes using  qualitative and 
quantitative systems, for ears, a qualitative system (Supplementary Figure S1, Tables S1, S2).  
Modified Pfirrmann Grading System and Spondyloarthritis Research Consortium of Canada 
(SPARCC) scores of the spine and whole-organ MRI scores (WORMS) of the knee were calculated 
(Supplementary Figures S2-S5, Table S3).[12, 13, 14] Institutional MRI protocols were followed. 
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 7
3D gait analysis was performed for 36 AKU patients (29 from SOFIA, 7 from the UK National 
Alkaptonuria Centre) and for a control group of 10 volunteers free from gait problems.[15, 16] Mean 
deviation of AKU gait from normality (MDPmean) was calculated using the MDP program 
(Supplementary Material, Figure S6).[17, 18] 
Disease questionnaires were used to calculate the modified questionnaire-based qAKUSSI  
(Supplementary Table S4).[19] 
Fasting blood samples and 24-hour urine samples were collected to measure metabolites and  
biomarkers of inflammation, cartilage, bone and tissue.  Serum and urine HGA were quantitated by 
liquid chromatography tandem mass spectrometry (LC-MS/MS) methods.[20, 21] Serum amyloid A 
(SAA) was analysed using a commercial assay. Quantitative determination of serum protein thiols and 
S-thiolated proteins was carried out.[22] Serum protein thiols were measured by colorimetric reaction 
with 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB).[23] S-thiolated proteins were measured.[24]  
Protein Thiolation Index (PTI) was calculated as the molar ratio between total S-thiolated proteins 
[RSSP, where RS is cysteine (CySSP), cysteinylglycine (CyGlySSP), homocysteine (HcySSP), γ-
glutamylcysteine (γGluCySSP) and glutathione (GSSP)] and the concentration of protein thiols.[25]  
The rate of connective tissue remodelling was analysed by the measurement in serum and urine of 
biomarkers of collagen and other extracellular matrix protein formation and degradation using 
competitive and sandwich ELISAs developed at Nordic Bioscience (Supplementary Table S5). The 
assays were run according to the standard procedure detailed in the references in Supplementary Table 
S5. 
 
Quality of Life was assessed using HAQ, SF-36 and KOOS questionnaires.[26, 27. 28]  
 
STATISTICAL ANALYSIS 
Multiple linear and LOESS regression were the main analyses used. Outcome variables were plotted 
against age and regression analyses carried out. Comparisons with controls were made as appropriate. 
All analyses were conducted using SAS® version 9.3 and R version 3.3.2. 
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Results 
Thirty AKU patients (15 male, 15 female) were recruited. Mean age: 39 years for males, 37 years for 
females, mean BMI:  25 kg/m
2
 for males and 23 kg/m
2
 for females (Supplementary Tables S6-S8). 
EAR CARTILAGE BIOPSY, EYE AND EAR PHOTOGRAPHS  
Ear biopsies from 28 samples were processed. Figure 1 shows ear and eye ochronosis measured by 
biopsy and photographs plotted against age, together with regression lines Figure 1(a) shows 
percentage of pigmentation of whole ear biopsy. Fitted regression lines were: 
% ear pigmentation =-23.5+1.43×age   for males (age: p=0.001, gender: p=0.742, R2=0.39) 
% ear pigmentation =-26.9+1.43×age   for females. 
FIGURE 1 ABOUT HERE 
Age was statistically significant (p=0.001), but not gender. The fit of this model, and some of the 
following models, was not particularly good, but it does give a strong indication of the increase in 
pigmentation with age. 
Assessment of pigment intensity by measuring light absorption of whole cartilage biopsy revealed 
pigmentation in a patient aged 20. 
Figure 1(b) shows ear ochronosis measured from photographs. Ochronosis was not detected until the 
middle of the third decade; a LOESS (Local Regression) reflects this. Figure 1(c) shows qualitative 
eye ochronosis scores. Regression lines were: 
  Eye pigmentation =-7.3+0.36×age for males  (age: p<0.001, gender: p=0.448, R2=0.50) 
  Eye pigmentation =-8.7+0.36×age for females. 
Age was statistically significant, but gender not. Figure 1(d) shows the correlation of the qualitative 
and quantitative eye ochronosis scores (R
2
=0.83). 
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MRI SCANS AND GAIT ANALYSES  
MRI spine and left knee imaging were performed on 27 and 26 AKU patients respectively. Disc 
degeneration, measured using the modified Pfirrmann score, is shown in Figure 2(a) and marrow 
oedema results, indicated by the modified SPARCC score, are shown in Figure 2(b). Knee scores are 
shown in Figure 2(c). Increases of the MRI scores with age are clearly not linear; LOESS regressions 
are shown for the two spine scores. Both show significant increases starting in the third decade of life. 
The WORMS scores generally stay low over the age range with a few exceptions.  
FIGURE 2 ABOUT HERE 
Figure 2(d) shows the mean movement deviation profile (MDPmean) plotted against age for AKU 
patients and controls together with a linear regression line for controls and a LOESS regression for the 
AKU patients. Deviation from normal gait was found even in the younger patients, and a steep incline 
after 50 years.  
MDPmean =2.44–0.01×age for Controls. 
Supplementary Figures S7 and S8 show a linear clustering and a 2D visualisation of the AKU patients 
and controls.  
 
MODIFIED qAKUSSI   
Figure 3(a) shows total modified qAKUSSI plotted against age;  Figures 3(b)-(d) show its components 
parts of clinical features, spine rheumatology and non-spine rheumatology. The corresponding 
regressions  are: 
  qAKUSSI   = -8.53+1.15×age for males      (age: p<0.001, gender: p=0.780, R
2
=0.47) 
  qAKUSSI    = -10.41+1.15×age for females 
  qAKUSSI_clin  = -7.31+0.67×age for males      (age: p=0.001, gender: p=0.316, R
2
=0.36) 
  qAKUSSI_clin  = -12.35+0.67×age for females. 
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 10
  qAKUSSI_spine  = -1.32+0.22×age for males      (age: p=0.002, gender: p=0.076, R
2
=0.35) 
  qAKUSSI_spine =1.91+0.22×age for females. 
  qAKUSSI_nonspine  = 0.05+0.26×age for males      (age: p=0.017, gender: p=0.995, R
2
=0.20) 
  qAKUSSI_nonspine  = 0.03+0.26×age for females. 
There were no significant differences for gender; all regressions showed a significant increase with 
age.  
FIGURE 3 ABOUT HERE 
 
HGA, BIOMARKERS AND  METABOLITE ANALYSES  
Figure 4 shows some results obtained for HGA measurements, the inflammation biomarker, SAA, and 
connective tissue damage markers. Figures 4(a), (b) show serum HGA and HGA clearance against 
age. The regression equations are: 
  Serum_HGA  =17.4+0.28×age for males      (age: p=0.006, gender: p=0.465, R2=0.26) 
  Serum_HGA  =19.2+0.28×age for females 
  HGA_clearance  =1322-11.8×age for males      (age: p=0.007, gender: p=0.934, R
2
=0.26) 
  HGA_clearance  =1313-11.8×age for females 
 
Gender was not significant, but serum HGA significantly increased and HGA clearance significantly 
decreased with age. Supplementary Figure S9 shows 24-hour urine HGA plotted against age. 
 
Figures 4(c-e) show SAA, CyGlySSP and PTI plotted against age and fitted regression lines. SAA and 
PTI significantly increased with age, but with no significant difference between groups. The 
regression lines for CyGlySSP showed significantly different slopes and intercepts for groups.[19-22] 
  SAA   = 8.5+0.43×age for AKU       (age: p=0.047, group: p=0.667, R
2
=0.07)* 
  SAA   =10.8+0.43×age for Controls 
  CyGlySSP   =22.1-0.20×age for AKU     (age: p<0.001, group: p=0.005, 
  CyGlySSP   =25.4+0.04×age for Controls       (age*group interaction: p=0.002, R2=0.25) 
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 11
  PTI    =0.31+0.002×age for AKU (age: p=0.015, group: p=0.090, R2=0.14) 
  PTI    =0.28+0.002×age for Controls 
* Two outliers removed. 
Supplementary Figure S10 shows extra inflammatory and oxidative markers. 
FIGURE 4 ABOUT HERE 
Figures 4(f)-(h) show uC1M_cr, TIM and P1NP plotted against age together with regression lines. The 
regression lines for the two groups for uC1M_cr have marginally significantly different slopes and 
significantly different intercepts. TIM has significantly different slopes and intercepts for the two 
groups. P1NP significantly decreases with age for AKU patients and controls at the same rate, but 
with mean P1NP higher for AKU patients.  
  uC1M_cr  =3.59-0.05×age for AKU      (age: p=0.004, group: p=0.004, 
  uC1M_cr  =1.65-0.03×age for Controls     age*group interaction: p=0.056, R
2
=0.30) 
  TIM  =157+4.09×age for AKU       (age: p=0.047, group: p=326,  
  TIM   =223+0.52×age for Controls      age*group interaction: p=0.039, R
2
=0.30) 
  P1NP   =172-1.43×age for AKU       (age: p=0.022, group: p=0.002, R
2
=0.22) 
  P1NP  =121-1.43×age for Controls 
Supplementary Figure S11 shows the biomarkers not covered in the main text., plotted against age for 
AKU patients and controls. 
 
QUALITY OF LIFE 
 
Figure 5 shows 6 of the 33 quality of life measurements: HAQ Disability Index, HAQ Pain score, 
SF36 Physical Functioning score, SF36 General Health score, KOOS Sport and Recreation score and 
KOOS Quality of Life score. The regression equations were: 
 
  HAQ_DI   = -0.73+0.03×age for males      (age: p<0.001, gender: p=0.676, R
2
=0.61) 
  HAQ_DI    = -0.68+0.03×age for females 
  HAQ_Pain  = -0.81+0.05×age for males      (age: p<0.001, gender: p=0.533, R2=0.71) 
  HAQ_Pain  = -0.65+0.05×age for females. 
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 12
  SF36_PF   = 109.8-1.17×age for males      (age: p<0.001, gender: p=0.390, R
2
=0.36) 
  SF36_PF  =  117.3 -1.17×age for females. 
  SF36_GH  =  83.3-1.03×age for males      (age: p=0.001, gender: p=0.775, R
2
=0.35) 
  SF36_GH   = 85.5 -1.03×age for females. 
  KOOS_Sport_Rec  = 144.6-2.18×age for males      (age: p<0.001, gender: p=0.938, R
2
=0.60) 
  KOOS_Sport_Rec = 145.3-2.18×age for females. 
  KOOS_QoL  = 115.1-1.37×age for males      (age: p<0.001, gender: p=0.815, R
2
=0.45) 
  KOOS_QoL   =117.0-1.37×age for females. 
 
FIGURE 5 ABOUT HERE 
All these measures show significant worsening of health with age but no difference between genders. 
The other QoL measures are reported in the Supplementary Material (Figures S12-S14). 
Discussion 
The SOFIA study objective was to identify the earliest age when ochronosis, microscopic and 
macroscopic, can be detected in AKU patients. Firstly, we review the published information in 
childhood AKU.  
A natural history study in 2002 reported on 64 patients (ages 4 to 80 years), but described no clinical 
features in childhood.[29] A Slovak study, described childhood AKU 35 years ago, in 39 patients.[30] 
Dark urine was present in all. Pigmentary changes in axillary regions appeared at 8-10 years. Dark 
brown to black staining of ear cerumen was present even in childhood. Ear cartilage pigmentation in a 
12 year old patient, and scleral pigmentation in a 13 year old patient, was reported, although no 
photographs were taken. The reported youngest age of arthropathy was 24 years. One 6-month old 
presented with a kidney stone.[31]  
We are the first to report on direct tissue studies in AKU, reasoning that it might be possible to 
identify pigmentation in tissue that could not be identified through overlying skin. Percentage 
pigmentation within ear biopsies increases with age, females lagging behind males. Difference 
between genders was not statistically different, probably due to the small sample size. Pigmentation 
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was detected in a 20 year old female, so ochronosis can start in AKU patients before the age of 20. 
Eye ochronosis increased with age and was first detected at age 22 years. Externally, visible ear 
ochronosis was only detected after age 34 years.  
AKU patients had 24-hour urine HGA and serum HGA values much higher than those of controls, 
showing no correlation with age, or gender. Serum HGA increased with age, but with no difference 
between genders, co-existing with worsening AKU. Conversely, HGA clearance decreased with age. 
The inflammation biomarkers, SAA and serum protein thiols, increased with age with no significant 
difference between AKU patients and controls.  
uC1M, a marker of collagen type I degradation measured in urine, decreased with age in AKU patients 
and P1NP, a marker of collagen type I formation measured in serum, decreased with age in both AKU 
and control groups. Bones are the main source of collagen type I in the human body, therefore the 
results suggest the rate of bone remodelling decreases with age. C1M measured in urine could reflect 
the remodelling of the renal tissue, suggesting the degradation of collagen type I in the kidney is 
decreased compatibly with an increase in fibrogenesis in the kidneys.[32] This hypothesis needs 
further investigation. TIM, a marker of MMP-mediated titin degradation describing cardiac 
remodelling, increased with age in AKU patients but not in controls, indicating increased remodelling 
of heart muscle with disease progression. At present, it is not possible to establish a precise age at 
which the biomarkers change dramatically. Further studies are needed with more patients at younger 
age with matched controls. 
The modified Pfirrmann spine scores on MRI analysis show AKU patients are unlikely to demonstrate 
degenerative lesions before age 30 years, however above 35 years they frequently show degenerative 
disc changes and overall worse Pfirrmann scores.[12] Marrow oedema lesion results (modified 
SPARCC scores) also appear to significantly rise from age of 30 years.[13] Degeneration of the knee 
(WORMS score) did not appear to be associated with age up to the middle of the fourth decade.[14] 
Despite the lack of change in spine and joints at ages younger than 30 years, the gait analysis was 
abnormal early on. The mean of Mean Deviation Profiles (MDP) for gait was significantly higher for 
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AKU patients than for controls.[17, 18] The younger AKU patients all had high MDP values 
indicating that gait is affected at this early age.  
qAKUSSI scores increase with age, the mean increasing at a rate of 1.14 units per year. All qAKUSSI 
components (clinical, spine and non-spine) increase with age. Even at the ages between 16 and 20, 
scores well above zero have been observed. Clinically, this means that as AKU patients get older, they 
score higher on q-AKUSSI regardless of their gender, reflecting a worsening disease burden.  
Three QOL questionnaires showed pain increases and general quality of life decreases with age for 
AKU patients. For the HAQ questionnaire, deterioration starts around age 30 years, but this can be at 
the start of the second decade for some domains for some patients. For the SF36 questionnaire, 
physical functions steadily decrease with age. For the KOOS questionnaire, the functions decrease 
with age. Overall, the quality of life appears to seriously deteriorate from the third decade. 
The overall conclusion is that this study has shown that ochronosis starts at an early age, before 
adulthood, but was unable to assess the earliest age that it may start. Further data is needed from a 
paediatric study if this start point is to be established. 
 
The difficulties of carrying out a human natural history study of AKU can be overcome to some extent 
by studying mouse AKU.[9, 10]  With biochemistry similar to human, mice with AKU also develop 
ochronosis, results suggesting that ochronosis begins a short time after weaning and progresses 
linearly over time. The use of nitisinone from early on in the life of an AKU mouse completely 
prevented the appearance of ochronosis. When nitisinone was administered after ochronosis was 
established, it arrested further progression.  
 
The reason for carrying out this AKU study is because of the availability of a HGA-lowering and a 
disease modifying therapy in the form of an enzyme inhibitor nitisinone. To consider using nitisinone 
early in life requires justification in the form of early ochronosis or early morbidity. The present study 
suggests the presence of apparently irreversible ochronosis and morbidity early in life.  
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LEGENDS TO FIGURES 
Figure 1. (a) Ochronosis score from ear biopsy plotted against age with regression lines, (b) ear 
ochronosis measured from photographs plotted against age with LOESS regression line, (c) eye 
ochronosis measured from photographs plotted against age with regression lines, (d) total quantitative 
eye pigmentation expressed as pixel value score plotted against total qualitative eye pigmentation 
score. 
Figure 2. (a) MRI Pfirrmann scores plotted against age, (b) SPARCC scores plotted against age, (c) 
WORMS scores plotted against age, (d) MDPmean plotted against age. 
Figure 3. Modified qualitative alkaptonuria Severity Score Index (modified qAKUSSI): (a) total 
modified qAKUSSI, (b) qAKUSSI, clinical features, (c) aAKUSSI, spine rheumatology, (d) 
qAKUSSI, non-sp ne rhematology. 
Figure 4. (a) Serum HGA (µmol/L), (b) HGA clearance (ml/min),  (c) SAA (ng/ml), (d) CyGlySSP 
(µM), (e) PTI, (f) Urine C1M_cr (ng/(µmol), (g) Serum TIM (ng/ml), (h) Serum P1NP (ng/ml)  
Figure 5. Quality of life scores: (a) HAQ Disability Index, (b) HAQ Pain Score, (c) SF36 Physical 
Functioning score, (d) SF36 General Health score, (e) KOOS Sport and Recreation score, (d) KOOS 
Quality of Life score. 
 
Page 19 of 60
https://mc.manuscriptcentral.com/bmjinnov
BMJ Innovations
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 1
Supplementary Material: Subclinical Ochronosis Features In Alkaptonuria 
(SOFIA):An Open Cross-sectional study to determine age of onset of ochronosis and 
morbidity  
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ASSESSMENTS 
Ear Biopsy 
Each biopsy contained a disc of cartilage 4mm in diameter and 1-2 mm thick. The disc was bisected 
along the diameter and a thin slice of 0.8mm was taken from the cut face. This sample was examined 
using an Olympus SZH binocular microscope in darkfield mode at 7.5 X magnification. The biopsy 
section was photographed using a 9M pixels DCM 900 camera and images stored as TIFFS.  TIFFs 
were opened in Image J as 8-bit RGB images. An oval region of interest 3 mm long by 1 mm wide 
was selected and the mean colour intensity in the blue channel was quantified on 255 scale, 
transformed so that white=0 and black=255.  Following subtraction of the absorbance of non-
ochronotic tissue the % absorbance was calculated (non-ochronotic tissue=0 and completely 
ochronotic tissue =100). Presence of ochronotic pigmentation was confirmed by histology on serial 
sections followed by Schmorl staining and microscopy (data not shown). 
Eye and Ear quantitative and qualitative assessments  
For quantitative analysis. JPEG image files were converted into 8-bit grey scale images using Image J. 
The images were calibrated for both size and c lour for standardisation. Using the zoom function the 
temporal and nasal parts of the right and left eyes were analysed for conjunctival scleral pigmentation. 
Upon identification of pigmentation the free hand tool was used to draw around the area if a definitive 
boundary could be defined. The area, perimeter, standard deviation, mean, minimum and maximum 
pixel values were recorded for each region of pigmentation. If no definitive boundary was evident a 
sample within the area of pigmentation was taken for pixel value comparisons. The total quantitative 
score is the sum of the scleral and conjunctival pixel values in the temporal and nasal parts of the right 
and left eyes. The maximum pixel value for both the scleral and conjunctival pigmentation is 100 
representing the darkest intensity, therefore the maximum score for each eye is 400. 
Figure S1. An example of eye ochronosis  
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Table S1 Qualitative scoring system for eye photographs. The score for a patient is the 
sum of scores over the four regions. 
 
    
 
 
Table S2 Qualitative scoring system for ear photographs.  
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Assessment of MRI scans  
 
Figure S2. Sagittal STIR image of an example of high T2 signal within the disc with disc 
height loss. 
 
Figure S3. Sagittal T1 image of an example of high T1 signal (arrows) crossing the L3/4 
and L4/5 intervertebral discs representing interbody fusion.  
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Figure S4. Sagittal 3D volume spoiled echo sequence showing low signal foci in the 
hyaline cartilage consistent with chondrocalcinosis. 
 
Figure S5. Sagittal STIR sequence of the whole spine in three study participants. 5a is a 
26 year old female, 5b is a 43 year old male and 5c is a 67 year old female.  
 
5a: the youngest, shows no focus of marrow oedema and normal thoracic and lumbar intervertebral 
discs. 5b: 43 year old shows relatively advance disc degenerative changes with foci of bone marrow 
oedema at multiple vertebrae. 5c: with advanced endstage degeneration, there is interbody fusion at 
multiple levels but little oedema like signal return, mainly confined to the mobile non-fused levels 
(T2/3, T7/8 & T8/9). Note also the kyphotic deformity is much wore in 5c associated with the 
advanced disc degeneration. 
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Table S3 Scoring system for MRI scan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of the thoracic and lumbar spine: 
Modified Pfirrmann Grading System for thoracolumbar intervertebral disc degeneration 
• Each intervertebral disc space (12 thoracic, 5 lumbar) will be graded for degenerative 
changes using a modified Pfirrmann grading system which is an 8 point score on T2 
weighted images.  A total score for the T/L spine will be recorded. 
o Max score for a thoracolumbar spine =136 
• Additional observation per disc score 1 
o Presence of increase T2 signal within nucleus with disc height loss 
o Presence of increase T1 signal crossing disc (fusion) 
o Presence of insufficiency fracture 
 Max score =51 
SPARCC (Spondyloarthritis Research Consortium of Canada) grading of increase T2 signal 
abnormality on STIR for 6 of the most affected discovertebral units (DVU) 
• Maximum score per unit =18 
• Total maximum score for 6 DVUs =108 
Analysis of knee: 
WORMS score – semiquantitative multifeature scoring system 
• Cartilage signal & morphology – 8 point scale (0, 1, 2, 2.5, 3, 4, 5, 6), score 0-6 
o Max scores: 
 MFTJ =30, LFTJ =30, PFJ =24 
• Subarticular BM abnormality – score 0-3 
o Max scores 
 MFTJ =15, LFTJ =15, PFJ =12, Region S =3 
• Subarticular cysts – score 0-3 
o Max scores 
 MFTJ =15, LFTJ =15, PFJ =12, Region S =3 
• Bone attrition – score 0-3 
o Max scores 
 MFTJ =15, LFTJ =15, PFJ =12 
• Osteophytes – score 0-7 
o Max scores 
 MFTJ =35, LFTJ =35, PFJ =28 
• Ligament scores 
o Cruciates (anterior and posterior) 0/1 – intact/torn 
o Collaterals (medial and lateral) 0/1 – intact/torn 
 Combined ligment score =Cruciates+½ * collaterals 
• Menisci – score 0-6 (depending on scores for tears present in regions) 
• Synovial thickening and effusion – Score 0-3 for entire knee 
• Loose bodies – Score 0-3 for entire knee 
Maximum WORMS score for knee =335 
 
Additional factors 
• Presence of low intrachondral signal 
o Max scores 
 MFTJ =5, LFTJ =5, PFJ =4 
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Gait Analysis 
Data were collected using Vicon MX motion capture with nine optoelectronic cameras (T160 and 
T10) sampling at a frame rate of 100 Hz (Vicon, Oxford, UK). Fifteen reflective markers were placed 
on the lower limbs in accordance with the Helen Hayes model14 and patients were asked to walk 
barefoot at a self-selected speed along a 10m walkway (Supplementary Figure S6). Pre-processed data 
from the 45 (X, Y, Z) marker coordinates were analysed using a self-organising map (SOM Toolbox 
2.0
15
) in MATLAB (R2017a, The MathWorks Inc., Massachusetts, US) to calculate the multi-
dimensional deviation of AKU gait from normality. The marker coordinate data of patients and 
controls were expressed relative to a straight line fitted onto the progression of the centre of their 
pelvis followed by calculation of z-scores for each waveform to compensate for differences in marker 
offsets and amplitudes. The self-organising neural network was then used to calculate the mean 
deviation of AKU gait from normality (MDPmean)
16,17
 during three gait cycles of each patient, using the 
MDP freeware program16. Gait deviation for each patient was then calculated as the average of three 
walks, plotted against age 
Figure S6. Marker trajectories during gait and a stick figure of the pelvis and legs 
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Modified qAKUSSI assessment  
Table S4: Modified qAKUSSI scoring system:the overall scores are the totals over 
individual feature scores  
 
Non-spine Non-Rheumatology Clinical features  Scoring 
Eye Pigments (conjunctival, scleral, temporal and 
nasal) 
0,1,2,3,4,6,8 
Ear Pigments 0,1,2,3 
Prostate and kidney Stones 4 (per episode) 
Heart valve disease 8 
Hearing impairment 4 
Fracture 8 per fracture 
Muscle/ tendon/ ligament rupture 8 per rupture 
Non-spine Rheumatology  
Clinical joint pain score (2 for each large joint area; 14 large joint areas) 
Number of joint replacements (Each joint 4-Max 10 large joints) 
Spine Rheumatology  
Clinical Spinal pain score (4 each for cervical, thoracic, lumbar and 
sacroiliac) 
 
Table S4 summarises the clinical aspects that were assessed in the modified q-AKUSSI in SOFIA.   
Eye and ear pigmentations were scored from digital images taken by the clinical photography 
department at the Royal Liverpool University Hospital. They were independently scored by one 
assessor who was blinded to patient demographics and clinical details. For the other elements of the 
modified q-AKUSSI, case notes were reviewed. 
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Biomarkers 
Serum and urine HGA were quantitated by liquid chromatography tandem mass spectrometry (LC-
MS/MS) methods using an Agilent 6490 Triple Quadropole mass spectrometer with Jet-Stream 
electrospray ionisation coupled with an Agilent 1290 Infinity II UHPLC pump and autosampler. Ten 
microliters of sample were diluted either with 0.4μmol/L 
13
C6-HGA in 0.1% formic acid (v/v) in 
deionised water (acidified urine samples) or 0.2μmol/L 13C6-HGA in 0.1% formic acid (v/v) in 
deionised water (deproteinised serum samples). Separation was achieved on an Atlantis dC18 column 
(100 x 3.0mm, 3μm, Waters) maintained at 35°C.  Quantitation was achived using a matrix-matched 
seven point calibration curve and two product ion transitions for both HGA and its internal standard 
13
C6-HGA.       
 
Serum amyloid A (SAA) was analysed using a commercial 96-well plate solid phase sandwich 
Enzyme Linked-Immuno-Sorbent Assay (ELISA) (Human SAA, KHA0011, Invitrogen Life 
Technologies) according to manufacturer’s instruction. Plates were read on a VersaMax microplate 
reader using Ascent software (Thermo Scientific). SAA quantification was obtained against a second 
order polynomial standard curve generated with SAA standards. All the blanks, standards and samples 
were tested in duplicate. Quantitative determination of serum protein thiols and S-thiolated proteins 
was carried out. Serum protein thiols were measured by colorimetric reaction with 5,5’-dithiobis-(2-
nitrobenzoic acid) (DTNB). S-thiolated proteins were measured.  Protein Thiolation Index (PTI) was 
calculated as the molar ratio between total S-thiolated proteins [RSSP, where RS is cysteine (CySSP), 
cysteinylglycine (CyGlySSP), homocysteine (HcySSP), γ-glutamylcysteine (γGluCySSP) and 
glutathione (GSSP)] and the concentration of protein thiols. 
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Table S5. Markers of connective tissue damage measured in SOFIA 
Assay Specifications Measuring Measured in Reference 
C1M MMP-generated fragment of 
type I collagen 
Inflammation related to synovial 
membrane remodeling 
Serum (1) 
CTX-I Cathepsin-generated and cross-
linked fragment of type I 
collagen 
Bone resorption Serum (2) 
P1NP N-terminal pro-peptide of type 
I collagen 
Bone formation Serum (3) 
C2M MMP-generated fragment of 
type II collagen 
Cartilage remodeling Serum (4) 
C3M MMP-generated fragment of 
type III collagen 
Inflammation related to synovial 
membrane remodeling 
Serum (5) 
CRPM MMP-generated fragment of C-
reactive protein 
Local inflammation Serum (6) 
C6M MMP-generated fragment of 
type VI collagen 
General fibrosis Serum (7) 
VCANM MMP-generated fragment of 
versican 
Cardiovascular remodeling Serum (8) 
MIM MMP-generated fragment of 
mimecan 
Cardiovascular remodeling Serum (9) 
TIM MMP-generated fragment of 
cardiac-specific titin 
Cardiovascular remodeling Serum (10) 
U-CTX-II C-telopeptide of type II 
collagen 
Cartilage remodeling Urine (11) 
U-C3M MMP-generated fragment of 
type III collagen 
Renal fibrosis Urine (12) 
U-C1M MMP-generated fragment of 
type I collagen 
Renal fibrosis Urine n/a 
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RESULTS 
 Demographics  
A total of 30 AKU patients were recruited. Half of them were males. The mean age for all patients was 
38.1 years ranging from 16 years to 67 years. Tables S6, S7 and S8 summarise the demographics of 
this cohort. 
Table S6. Demographics of AKU cohort in SOFIA-age 
 
Table S7. Demographics of AKU cohort in SOFIA-weight 
 
Table S8. Demographics of AKU cohort in SOFIA-BMI 
 
 
Gait Analyses  
Figure S7:A 1D self-organising neural network forced a linear clustering of AKU 
patients (red) and controls (blue). Their age is indicated by the size of circles. 
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Figure S8:A 2D scatter plot visualising the topological relationships between AKU 
patients (red)  and controls (blue) as a function of their age (circle size).  
 
 
 
 
 
 
 
 
HGA 
Figure S9. 24-hour urine HGA plotted against age 
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Figure S10. Inflammatory and oxidative markers  
 
  PSH  =497.1-1.54 × age for AKU     (age:p=0.008, group:p=0.103, R
2
 =0.16) 
  PSH  =520.7-1.54 × age for Controls 
  CySSP  =133.5+0.22 × age for AKU     (age:p=0.383, group:p=0.209, R
2
 =0.04) 
  CySSP  =125.5+0.22 × age for Controls      
  HcySSP  =3.76+0.11 × age for AKU     (age:p=0.121, group:p=0.792, R
2
 =0.04) 
  HcySSP   =4.24+0.11 × age for Controls 
  γGluCySSP   =0.81-0.01 × age for AKU     (age:p=0.001, group:p=0.0827,  
  γGluCySSP   =0.54-0.00 × age for Controls     age*group interaction:p=0.008, R
2
 =0.19)      
  GSSP =1.60+0.00 × age for AKU     (age:p=0.907, group:p=0.395, R
2
 =0.01) 
  GSSP  =1.51+0.00 × age for Controls      
  RSSP  =157.8-0.22 × age for AKU     (age:p=0.446, group:p=0.348 R
2
 =0.03) 
  RSSP =150.8-0.22 × age for Controls 
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Connective tissue biomarkers 
Figure S11: Levels of the biomarkers plotted against age in AKU and control samples  
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  C1M  =22.01+0.11×age for AKU     (ag:p=0.269, group:p=0.933, R
2
=0.02) 
  C1M  =22.23+0.11×age for Controls 
  C2M  =0.43+0.00×age for AKU     (age:p=0.335, group:p=0.458, R2=0.03) 
  C2M  =0.39+0.00×age for Controls      
  C3M  =10.61+0.01×age for AKU     (age:p=0.869, group:p=0.043, R2=0.07) 
  C3M  =12.33+0.01×age for Control 
  C6M  =15.74-0.01×age for AKU     (age:p=0.893, group:p=0.080, R
2
=0.05) 
  C6M  =18.42-0.01×age for Controls      
  CRPM =9.85+0.01×age for AKU     (age:p=0.684, group:p=0.008, R
2
=0.12) 
  CRPM  =11.70+0.01×age for Controls      
  CTX_I  =1.22-0.02×age for AKU     (age:p<0.001, group:p=0.527, R
2
=0.22) 
  CTX_I =1.15-0.02×age for Controls 
  MIM =26.57+0.11×age for AKU     (age:p=0.543, group:p=0.634, R
2
=0.01) 
  MIM =28.84+0.11×age for Controls      
 
  VCANM =1.40+0.00×age for AKU     (age:p=0.152, group:p=0.343, R
2
=0.05) 
  VCANM =1.47+0.00×age for Controls 
  uC1M =15.57-0.09×age for AKU     (age:p=0.195, group:p=0.003, R
2
=0.16) 
  uC1M =10.29-0.09×age for Controls 
  uC3M =606+0.16×age for AKU     (age:p=0.953, group:p<0.001, R
2
=0.48) 
  uC3M =120+0.16×age for Controls      
  uCTX_II =-4.19+0.27×age for AKU     (age:p<0.001, group:p=0.202,  
  uCTX_II =1.27+0.06×age for Controls     age*group interaction:p=0.034, R
2
=0.45)** 
  uC3M_cr =107-0.79×age for AKU     (age:p=0.121, group:p<0.001, R
2
=0.35) 
  uC3M_cr =40-0.79×age for Controls 
  uCTX_II_cr =2.19-0.02×age for AKU     (age:p=0.091, group:p=0.011, R2=0.14) 
  uCTX_II_cr =1.30-0.02×age for Controls 
** For patients with age > 25 
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Quality of Life 
HAQ 
A total of thirty patients completed the HAQ questionnaire. This index considers how arthritis has an 
impact on everyday life. Total score is between 0–3.0, in 0.125 increments. Increasing scores indicate 
worse functioning (score 0=no functional impairment; score 3=complete impairment). 
These scores were correlated with age. The sub-figures in Figure S11 show a clear pattern:as AKU 
patients become older, they struggle with their Activities of Daily Living (ADLs); with the exception 
of “eating” all other domains show significant correlation with age. Sub-Figure, HAQ-Pain, shows 
that as patients get older, the burden of AKU arthritis pain increases and the debilitating effects of the 
ochronosis become overt (Sub-Figure, HAQ-Disability Index).  
SF36 
A total of 29 patients completed this questionnaire. Correlations with age are shown in the sub-figures 
of Figure S12. All questions are scored on a scale from 0 to 100 (highest level of functioning 
possible=100, complete loss of function=0). It is clear that as AKU patients get older, their energy 
levels and physical functions decrease. In addition, their general health deteriorates and they 
experience more pain. Nonetheless, emotionally, they remain resilient (Sub-Figure, SF36-Limitations 
due to emotional problems). 
KOOS 
Twenty seven patients completed this questionnaire. Correlations with age are shown in the sub-
figures of Figure S13. As seen with the previous two tools, there is a clear deterioration in QoL, across 
all domains, with age. This can be detected as early as 35 year of age. 
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Figure S12: HAQ 
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Figure S13: SF_36 
 
 
  
Page 37 of 60
https://mc.manuscriptcentral.com/bmjinnov
BMJ Innovations
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 19
 
Figure S14: KOOS 
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5
th
 October2018 
 
The Editor 
BMJ Innovations 
 
Dear Sir/madam 
 
I submit this manuscript entitled ‘Subclinical Ochronosis Features In Alkaptonuria: A Cross-
Sectional Study’ on behalf of my colleagues (and my co-authors) for consideration of publication in 
the British Medical Journal Innovations. All of my co-authors have contributed to the manuscript. 
Since a disease modifying therapy is now available for alkaptonuria, we believe that this paper is 
timely in addressing the age to begin this disease modifying therapy. 
 
Yours sincerely 
 
 
Dr Lakshminarayan Ranganath 
Chief Investigator in SOFIA 
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SFig 1 - Supplementary Fig 1  
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SFig 2 - Supplementary Fig 2  
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